Medapp

Medapp R&D Expenses

Research & Development Expenses of Medapp (MDA.WA) as of Nov 21, 2026.

R&D Expenses

0.00PLN

Last updated:

Research & Development Expenses of Medapp is 2025 0.00 PLN. Research & Development Expenses of Medapp was 2024 0.00 PLN. It decreases by % lower compared to the previous year.

The Medapp R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2018
0.00 PLN
Jan 1, 2019
0.00 PLN
Jan 1, 2020
0.00 PLN
Jan 1, 2021
0.00 PLN
Jan 1, 2022
0.00 PLN
Jan 1, 2023
0.00 PLN
Jan 1, 2024
0.00 PLN
Jan 1, 2025
0.00 PLN
The Medapp R&D Expenses history
YEARR&D ExpensesYoY
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medapp Stock analysis

What does Medapp do? MedApp SA generates revenue through its mobile marketing solutions in the medical field, primarily via the Carna Life software application. Carna Life functions as a telemedicine platform enabling doctors and patients to communicate, with features including data upload and download for test results, offline data review, and graphical statistics. The company serves healthcare providers and patients seeking telemedicine services, focusing on the Polish market through its Krakow headquarters. Moonrock Enterprise SA controls MedApp SA, leveraging its software for medical communication solutions. The firm's revenue model centers on the Carna Life application, which provides telemedicine services by facilitating secure data exchange between doctors and patients. Patients use the app to upload test results, while doctors interpret them through the platform, supported by offline functionality and data visualization tools. This system targets medical professionals and patients in Poland, operating within the telemedicine sector without external partnerships or additional branded products. MedApp SA's business relies solely on the Carna Life telemedicine system, which offers both online and offline modes for data management. The application includes statistics, visualizations, and tables for interpreted medical data, serving as a communication channel between healthcare providers and patients. Controlled by Moonrock Enterprise SA, the company monetizes its software through direct sales to medical institutions and patient users in the Polish healthcare market. Medapp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medapp stock

On Eulerpool you can find the complete historical development of Research & Development Expenses Medapp since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Medapp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Medapp

All Key Metrics — Medapp